Applied Molecular Oncology, Ontario Cancer Institute, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Clin Cancer Res. 2012 Jan 1;18(1):196-206. doi: 10.1158/1078-0432.CCR-11-1759. Epub 2011 Nov 10.
From the published literature, we identified 23 germ line sequence variants in 17 genes from hypothesis-generating studies that were associated with prognosis of head and neck cancer, including sequence variants of DNA repair (ERCC1, ERCC4, ERCC5, MSH2, XPA, ERCC2, XRCC1, XRCC3), DNA methylation (DNMT3B), cell cycle and proliferation (CCND1, TP53), xenobiotic metabolism (GSTM1, GSTT1, CYP2D6), metastatic -potential (MMP3), immunologic (CTLA4), and growth factor pathways (FGFR4). The purpose of this study was to validate the role of these 23 sequence variants for overall (OS) and disease-free survival (DFS) in a large, comprehensive, well-annotated data set of patients with head and neck cancer.
We genotyped these sequence variants in 531 patients with stage I and II radiation-treated head and neck cancer (originally recruited for an alpha-tocopherol/beta-carotene placebo-controlled secondary prevention study), and analyzed using Cox proportional hazards models, stratified by treatment arm, adjusting for clinical prognostic factors.
Two OS associations were statistically significant for each variant allele when compared with the wild-type: CTLA4: A49G [rs231775; adjusted HR (aHR), 1.32 (1.1-1.6); P = 0.01] and XRCC1: Arg339Gln [rs25487; aHR, 1.28 (1.05-1.57); P = 0.02]. Both of these sequence variants had significant results in the opposite direction as prior published literature. Two DFS associations were of borderline significance in the same direction as prior literature: ERCC2: Lys751Gln [rs13181; aHR, 0.80 (0.6-1.0); P = 0.05] and TP53: Arg72Pro [rs1042522; aHR, 1.28 (1.0-1.6); P = 0.03], comparing number of variant alleles with reference of zero variants.
None of the prognostic sequence variants previously published was validated for OS in our patients with early-stage radiation-treated head and neck cancer, though rs1381and rs1042522 had borderline significant association with DFS.
从已发表的文献中,我们在假设生成研究中确定了 17 个基因中的 23 个种系序列变异,这些变异与头颈部癌症的预后相关,包括 DNA 修复(ERCC1、ERCC4、ERCC5、MSH2、XPA、ERCC2、XRCC1、XRCC3)、DNA 甲基化(DNMT3B)、细胞周期和增殖(CCND1、TP53)、异生物质代谢(GSTM1、GSTT1、CYP2D6)、转移潜能(MMP3)、免疫(CTLA4)和生长因子途径(FGFR4)的序列变异。本研究的目的是在一个大型的、全面的、注释良好的头颈部癌症患者数据集,验证这些 23 种序列变异与头颈部癌症患者的总生存(OS)和无病生存(DFS)的关系。
我们对 531 名接受 I 期和 II 期放疗的头颈部癌症患者(最初招募参加α-生育酚/β-胡萝卜素安慰剂对照二级预防研究)进行了这些序列变异的基因分型,并使用 Cox 比例风险模型进行分析,按治疗臂分层,根据临床预后因素进行调整。
与野生型相比,每种变异等位基因与 OS 有统计学意义的两个关联:CTLA4:A49G[rs231775;调整后的 HR(aHR),1.32(1.1-1.6);P = 0.01]和 XRCC1:Arg339Gln[rs25487;aHR,1.28(1.05-1.57);P = 0.02]。这两个序列变异的结果与之前发表的文献的方向相反。DFS 有两个关联具有与之前文献相同的边界意义:ERCC2:Lys751Gln[rs13181;aHR,0.80(0.6-1.0);P = 0.05]和 TP53:Arg72Pro[rs1042522;aHR,1.28(1.0-1.6);P = 0.03],比较的是参考零变异时的变异等位基因数量。
在我们接受早期放疗的头颈部癌症患者中,之前发表的预测序列变异中没有一个与 OS 得到验证,尽管 rs1381 和 rs1042522 与 DFS 有显著的相关性。